BlackRock Reveals 1.58% Holding in Mural Oncology

BlackRock, Inc. (NYSE:BLK), an investment management company, revealed a 1.58% stake in Mural Oncology plc (NASDAQ:MURA), an Ireland-based clinical-stage oncology giant. The disclosure was made on June 4, 2025, while complying with the Takeover Rules 2022.

As of June 3, 2025, BlackRock, Inc. (NYSE:BLK) has 272,974 ordinary shares of Mural Oncology plc (NASDAQ:MURA), with 15 additional shares tied to cash-settled derivatives. There’s nothing short in the mix, just a solid position in the healthcare sector.

Jim Cramer Buys BlackRock, Inc. (BLK): “I’m Down on it -But Long-Term, it’s a Buy”

A professional asset manager making an investment decision at their office.

This comes particularly at a time when Mural Oncology plc (NASDAQ:MURA) is seeking a corporate move that could change its ownership landscape. BlackRock, for its part, hasn’t yet unveiled any side deals or incentives behind this investment.

This diversification into the healthcare industry has led to the upside of BlackRock, Inc. (NYSE:BLK), with the stock now rising. In light of this, Wells Fargo analysts have raised the price target from $1,035 to $1,105, with an unchanged Overweight rating.

BlackRock, Inc. (NYSE:BLK) is an investment company providing services to institutional, intermediary, and individual investors. Incorporated in 1988, the giant aims to enhance its clients’ financial well-being.

While we acknowledge the potential of BLK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than BLK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure. None.